somc cancer services annual report€¦ · somc case accession summary for combined calendar years...

(740) 356-7490www.somc.org/cancer/reports

SOMC Cancer Center1121 Kinneys Lane | Portsmouth, OH 45662

SOMC Cancer Services

Annual Report2016

www.somc.org/cancer/reports/ (740) 356-7490

Contents1

6

8

9

13

13

14

17

Introduction and 10-Year Milestones

SOMC Case Accession Summary for Combined Calendar Years 2013, 2014, and 2015

SOMC Site Distribution Data Illustration for Diagnosis Years 2013, 2014, and 2015

Accountability Measures and Quality Improvement Measures

Monitoring Compliance with Evidence-Based Guidelines

Studies of Quality

Studies of Quality Improvement

Cancer Committee Members 2016

SOMC Cancer Center1121 Kinneys Lane

Portsmouth, OH 45662

the somc cancer services

2016 Annual Report


1

IntroductionDear Colleagues,

It is with sincere pleasure that I present to you the 2016 SOMC Cancer Center Annual Report.

Ironically, over 10 years ago I walked into the building of the SOMC Cancer Center for the first time. The tour of the center lead by Wendi Waugh and the people that I met in the course of interviews contributed to my decision to relocate from New York City to Portsmouth, Ohio and join the SOMC family.

I thought it appropriate to reflect on the last 10 years with over 10 major milestones of this incredible team.

Breast Cancer Compassion Fund-2007

Shortly after joining SOMC, we recognized there was an opportunity to support breast cancer patients with small items to complement their care such as camisoles to hold the drain tubes and money for transportation. Since the fund’s inception in late 2007, the fund has grown to be known as the Paint IT Pink campaign. Over the years, the funds from the events have assisted hundreds of women with camisoles and surgical bras, medication co-pays, genetic counseling, transportation, food, housing, and so much more. In fact, the fund grew beyond serving breast cancer patients and now serves patients with any diagnosis of cancer under care at SOMC. To date, more than $1 million dollars has been donated to assist our friends and neighbors in need. One of the most recent expansions of the fund includes weekly yoga and scheduled Reiki sessions.

Partial Breast Irradiation-2008

The team also sought to provide breast cancer patients access to partial breast irradiation in the form of internal, catheter-based High Dose Radiation (HDR) Therapy. This goal was accomplished in December 2008 when the first patient received treatment at the SOMC Cancer Center. Establishing the service was no easy task as a special unit, a special room, and a dedicated trained team was required. The volume of patients who would benefit from the technology was low and the investment outweighed the returns, yet together we found an innovative way to introduce the service. To

date, over 140 women have been served. Those numbers may seem small but are large for the ladies who visited the center for 5 days rather than 35 days. Over the years, we have perfected the service and in 2013 the SOMC Cancer Center and the performing providers were designated as Center of Excellence in Accelerated Partial Breast Irradiation. Following strict guidelines from the American Society of Breast Surgeons and the American Society of Brachytherapy, we are able to offer a wider group of women this innovative treatment option with equal outcomes.


2

Measuring Performance with National Quality Forum Indicators-2009

Our extremely pro-active cancer committee sought to compare SOMC performance on quality indicators to nationally recognized guidelines on the Cancer Services Strategic Value Dashboard. The group settled on six indicators and tracked performance. The performance was later published in the 2010 Annual Report and this understanding of the quality indicators led to early adoption of the Rapid Quality Reporting System indicators from the Commission on Cancer. In fact, because the team had already been measuring performance, implementing a process to identify patients who might not have been on track to receive appropriate care was identified. Many action plans to perfect performance have led to stellar results and paved the way for value-driven cancer care.

Image-Guided Radiation Therapy and Stereotactic Ablative Radiation Therapy-2010

In 2010, the Radiation Oncology department within the cancer center added the capability to see and image the patient before the radiation treatment is administered. This enhanced imaging led to the implementation of Stereotactic Ablative Radiotherapy (SABR). SABR is a technique designed to deliver highly focused radiation therapy with pinpoint precision. The technique also reduces the number of treatments that the patient is prescribed, thereby decreasing patient inconvenience while maintaining equal or better cure rates.

Palliative Care-2011

A palliative care team has a unique role in addressing the needs of patients who are terminally ill and bridging a gap to hospice. The palliative care team is focused on enhancing quality of life by assisting the patient and family with making decisions, assessing and managing symptoms and pain; and meeting the emotional, spiritual and practical needs of this patient population. Since the inception of the palliative care program in 2011, we have expanded its convenience for patients and beginning in April of 2014, the palliative care provider hosts a clinic within the SOMC Cancer Center.


3

Clinical Trials-2012

In 2012 Cancer Services began offering National Cancer Institute Clinical Trials. Offering clinical trials is an important component of comprehensive cancer care. Not only do trials offer patients with options for treatment, it also allows those in our community to contribute to cancer research in the continuous quest to win the war against cancer. Since the inception of clinical trials at SOMC, the organization has been recognized as having the highest number of trials accrued and our clinical trials nurse, Jamie Arnett has contributed to a published article and was selected to represent the Midwest Region in the Lung-Map project.

Mammograms without an Order-2013

In 2013, the team set out to make it easier for women to receive an annual mammogram. With an already established relationship with Susan G. Komen of Columbus to financially assist women who were uninsured or underinsured with access to testing, the team sought to make sure that women could schedule a mammogram without having to visit a provider’s office to receive an order. The team established a process through which an order could be obtained and if the patient had not received a clinical exam, it was provided to the patient through collaboration with a provider in the Breast Center at the time of her mammogram.

Psychosocial Distress and Survivorship Care Plans-2014

Unsurprisingly based on the history of the program, the SOMC Cancer Center had assessed patients for distress upon first visit and intermittently when appropriate for many years. The center was also an early adopter of Survivorship Care Plan initiation. Still, both of these items were demonstrated increasingly in the literature as emerging to be top priorities in cancer care and two Quality Studies were initiated to study the process and measure results. The results of the these studies indicated that although some process was established, significant opportunity existed to ensure the services were received by all cancer patients cared for through the SOMC Cancer Center. Sub-committees worked diligently over the course of 2014 on Quality Improvement projects that resulted in major improvements in the assessment, content, and delivery.


4

Genetic Counseling and Lung Navigation-2015

Genetic Counseling became available to patients of our community through the purchase of telemedicine equipment and a partnership with OhioHealth to gain access to certified genetic counseling in 2013. Despite access, in 2015 an evaluation of the access was conducted revealing under-utilization particularly for women of highest risk. A sub-committee of the SOMC Cancer Committee met and developed a Standard of Care (SOC) for Genetic Counseling that was deployed to medical staff. Since deployment of the SOC, genetic counseling provided prior to medical decision making has immensely improved. In addition, the committee published three other SOCs and formalized a method of creating standards of cancer care for medical staff.

Many of the lessons we have learned and items we sought to improve in breast care have been applied to other cancer sites and most notably, lung cancer. In late 2015, with the assistance of Dr. Elie Saab, the cancer service line introduced a dedicated lung navigator, a lung nodule clinic, and a low-dose lung cancer screening program. The service line is growing exponentially as we work toward finding lung cancer at a much earlier stage where the chance of cure is greatly improved. Now, with the addition of our newest thoracic surgeon, Jeremiah Martin, MD, our lung team is complete.

Molecular Testing and the Oncology Care Model-2016

Cancer is a complex disease and often requires a multifaceted approach that includes several modalities such as surgery, chemotherapy, and radiation. But the emergence of a new modality, molecular management is upon us. Personalized medicine assists in applying targeted therapies. Because of this, the cancer committee initiated reflex testing for certain cancer types. The reflex testing will ensure that patients are evaluated for mutations early and targeted therapies can be applied without delaying the treatment course initiation. In addition, cancer committee carried forward a policy to medical staff to ensure that all outside pathology is reviewed by our pathologists prior to the initiation of treatment at SOMC.

Lastly, the SOMC Cancer Center was selected to participate in the Oncology Care Model (OCM). Participation began in July 2016. OCM encourages practices to improve care and lower costs introducing “value-based cancer care”. The model is one of the first CMS physician-led specialty care models and only 400 practices across the nation were selected to participate. Participating practices will ensure treatment follows nationally recognized clinical guidelines with an emphasis on person-centered care and patients will receive timely, coordinated treatment. The SOMC Cancer Center will undergo on-site audits and submit quality and clinical metrics on a quarterly basis for five years. This model is likely to shape the future of oncology care delivery nationwide.


5

2017 and Beyond

The future is bright. A planned expansion of cancer services is fully underway and construction is set to begin in early 2017. The expansion will consolidate breast care within the walls of the SOMC Cancer Center as the service line consolidation is planned for 2017. Breast imaging, breast biopsy, breast surgical services, and a high-risk clinic are included in the project. A separate expansion project will add a new linear accelerator to the upper level of the cancer center. This state-of-the-art linear accelerator will have the capability to provide the very latest of treatment techniques to patients including Stereotactic Radiosurgery.

We expect to undergo a first-time survey for accreditation by the National Accreditation Program for Breast Centers (NAPBC) as well as re-accreditation from the American College of Surgeons Commission on Cancer and American College of Radiology in Radiation therapy.

Thank you for allowing me to share and bask in the accomplishments of our program. It has been my pleasure to serve as the SOMC Cancer Liaison Physician of the program since my arrival at SOMC and I look forward to future growth and accomplishments benefitting the community we serve as I fulfill the role of Cancer Committee Chair and Quality Improvement Coordinator.

Sincerely,Vincent M Scarpinato M.D., F.A.C.S., M.B.A.


6

SOMC Case Accession Summary for Combined Calendar Years 2013, 2014, & 2015

Total % Male % Female %

Oral Cavity & Pharynx 27 2.3 18 3.6 9 1.3

Tongue 10 0.9 7 1.4 3 0.4

Salivary Glands 2 0.2 1 0.2 1 0.1

Gum & Other Mouth 2 0.2 1 0.2 1 0.1

Nasopharynx 1 0.1 1 0.2 0 0

Tonsil 5 0.4 3 0.6 2 0.3

Oropharynx 2 0.2 2 0.4 0 0

Other Oral Cavity & Pharynx 1 0.1 0 0.0 1 0.1

Digestive System 186 15.9 104 20.9 82 12.1

Esophagus 16 1.4 14 2.8 2 0.3

Stomach 12 1.0 7 1.4 5 0.7

Small Intestine 5 0.4 2 0.4 3 0.4

Colon Excluding Rectum 94 8.0 48 9.7 46 6.8

Cecum 8 4 4

Ascending Colon 4 2 2

Hepatic Flexure 0

Appendix 5 2 3

Splenic Flexure 1 0 1

Descending Colon 1 1 0

Sigmoid Colon 9 2 7

Large Intestine, NOS 61 35 26

Rectum & Rectosigmoid 27 2.3 17 3.4 10 1.5

Rectosigmoid Junction 3 2 1

Rectum 24 15 9

Anus, Anal Canal & Anorectum 3 0.3 0 0 3 0.4

Liver & Intrahepatic Bile Duct 10 0.9 7 1.4 3 0.4

Gallbladder 2 0.2 0 0 2 0.3

Peritoneum, Omentum, Mesentery 2 0.2 0 0 2 0.3

Pancreas 13 1.1 7 1.4 6 0.9

Respiratory System 274 23.4 148 29.8 126 18.7

Larynx 8 0.7 4 0.8 4 0.6

Lung & Bronchus 266 22.7 144 29.0 122 18.1


7

Soft Tissue 7 0.6 7 1.4 0 0.0

Skin Excluding Basal & Squamous 60 5.1 33 6.6 27 4.0

Melanoma -- Skin 54 4.6 30 6.0 24 3.6

Other Non-Epithelial Skin 6 0.5 3 0.6 3 0.4

Breast 275 23.5 1 0.2 274 40.6

Female Genital System 47 4.0 0 0 47 7.0

Cervix Uteri 6 0.5 0 0 6 0.9

Corpus & Uterus, NOS 32 2.7 0 0 32 4.7

Ovary 7 0.6 0 0 7 1.0

Vagina 1 0.1 0 0 1 0.1

Vulva 2 0.2 0 0 2 0.3

Male Genital System 75 6.4 75 15.1 0 0

Prostate 69 5.9 69 13.9 0 0

Testis 3 0.3 3 0.6 0 0

Penis and Other 3 0.3 3 0.6 0 0

Urinary System 41 3.5 30 6.0 11 1.6

Urinary Bladder 33 2.8 26 5.2 7 1.0

Kidney, Renal Pelvis & Ureter 5 0.4 2 0.4 3 0.4

Brain & Other Nervous System 7 0.6 5 1.0 2 0.3

Endocrine System 36 3.1 8 1.6 28 4.1

Thyroid 35 3.0 7 1.4 28 4.1

Other Endocrine including Thymus 1 0.1 1 0.2 0 0

Lymphoma 45 3.8 18 3.6 27 4.0

Hodgkin Lymphoma 1 0.1 0 0.0 1 0.1

Non-Hodgkin Lymphoma 44 3.8 18 3.6 26 3.9

Myeloma 10 0.9 7 1.4 3 0.4

Leukemia 29 2.5 15 3.0 14 2.1

Lymphocytic Leukemia 7 0.6 5 1.0 2 0.3

Myeloid &Monocytic Leukemia 10 0.9 2 0.4 8 1.2

Other Leukemia 12 1.0 8 1.6 4 0.6

Mesothelioma 2 0.2 2 0.4 0 0.0

Kaposi Sarcoma 1 0.1 1 0.2 0 0

Miscellaneous 50 4.3 25 5.0 25 3.7

Total 1,172 497 675

SOMC Case Accession Summary for Combined Calendar Years 2013, 2014, & 2015


8

SOMC Site Distribution Data Illustration for Diagnosis Years 2013, 2014, & 2015

Thyroid - 28 (4%)

Lung & Bronchus - 122 (18%)

Breast - 274(41%)

Kidney & Renal Pelvis - 3 (<1%)

Ovary - 7 (<1%)

Uterine Corpus - 32 (5%)

Colon & Rectum - 56 (8%)

Non-Hodgkin Lymphoma - 26 (4%)

Melanoma of the Skin - 24 (4%)

Leukemia - 12 (2%)

All Other Sites - 89 (13%)

Oral Cavity & Pharynx - 18 (4%)

Lung & Bronchus - 144 (29%)

Pancreas - 7 (1%)

Kidney & Renal Pelvis - 2 (<1%)

Urinary Bladder - 26 (5%)

Prostate - 69 (14%)

Colon & Rectum - 65 (13%)

Non-Hodgkin Lymphoma - 18 (4%)

Melanoma of the Skin - 30 (6%)

Leukemia - 15 (3%)

All Other Sites - 103 (21%)

The number next to the site represents the number of cases diagnosed at SOMC diagnosis years 2013, 2014 and 2015 combined and the number in parenthesis represents the

percentage this cancer site represents at SOMC for those same diagnosis years.


9

Accountability and Quality Improvement Measures (Standard 4.4 and 4.5)

SOMC Cancer Service’s accreditation by the American College of Surgeons Commission on Cancer allows the center to compare treatment standards and quality of care. The Commission on Cancer partners with the National Quality Forum (NQF), the American Society for Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). These organizations have identified quality cancer measures. The following graphs demonstrate the results of SOMC Cancer Care team compared to all approved East Central ACS, all approved programs with a similar type of accreditation as we hold-Community Cancer Program-(CCP), and all Commission on Cancer (CoC) approved programs. We are very proud of our results. These results represent the latest published data, calendar year 2014.

Note: If no 2014 data existed for SOMC the graph is not published here.

Radiation is Administered within 1 Year of Diagnosis

for Women Receiving Breast Conserving Surgery

2014 Performance

Aromatase Inhibitor is Considered or Administered

within 1 Year of Diagnosis for AJCC T1c or IB-III Hormone Receptor

+ Breast Cancer

2014 Performance

89

90

91

92

93

94

95

96

SOMC EastCentral ACS CoCCommunityCancerCenters

AllApprovedCoCPrograms

84

86

88

90

92

94

96

98

100

102



Breast Cancer

www.somc.org/cancer/report/ (740) 356-7490

10

Radiation Therapy is Considered or Administered

following Mastectomy for Women with ¹ 4 + Nodes

2014 Performance82

84

86

88

90

92

94

96

98

100

102



Breast Conservation Surgery Rate for Women with AJCC Clinical Stage 0,I, or II Breast Cancer

2014 Performance

Image or Palpation-Guided Needle Biopsy is

Performed to Establish Breast Cancer Diagnosis

2014 Performance

Combination Chemotherapy is Considered or

Administered within 4 months for AJCC T1cNO, or Stage IB-III Hormone

Receptor Positive Breast Cancer Women <70

2014 Performance

90.5

91

91.5

92

92.5

93

93.5

94

94.5

95

95.5



0

10

20

30

40

50

60

70

80

90

100



86

88

90

92

94

96

98

100

102




Adjuvant Chemotherapy is Considered or Administered

within 4 months for AJCC III Colon Cancer

2014 Performance

At Least 12 Regional Nodes are Removed for Resected Colon Cancer

2014 Performance

Endoscopic, Laparoscopic, or Robotic performed for

all Endometrial Cancer all Stages Excluding Stage IV

2014 Performance

82

84

86

88

90

92

94

96

98

100

102



80

82

84

86

88

90

92

94

96

98

100



0

20

40

60

80

100

120



Chemotherapy Administered to Cervical Cancer Patients

who Received Radiation for Stages IB2-IV or with

Positive Pelvic Nodes, Positive Surgical Margin, and/or

Positive Parametrium

2014 Performance

82

84

86

88

90

92

94

96

98

100

102



11

Cervical Cancer

Colon Cancer

Endometrial Cancer


Systemic Chemotherapy is Administered within 4 Months Pre-op or 6 Months Post-op for Resected Lymph Node + NSCLC

2014 Performance88

90

92

94

96

98

100

102



Surgery is not the First Course of Treatment for

cN2, M0 Lung Cases

2014 Performance88

90

92

94

96

98

100

102



12

Lung Cancer

Preoperative Chemo and Radiation are Administered for Clinical AJCC T3NO,

T4NO, or Stage III; or Postoperative Chemo and Radiation are Administered within

180 Days of Diagnosis for Clinical AJCC T1-2NO with Pathologic AJCC T3NO, T4NO, or

Stage III; or Treatment is Recommended; for patient <80 Receiving Resection

2014 Performance

At Least 10 Regional Nodes are Removed for AJCC IA, IB, IIA, and IIB Resected NSCLC

2014 Performance0

10

20

30

40

50

60

70

80



0102030405060708090100

SOMC EastCentralACS

CoCCommunityCancerCenters

AllApproved

CoCPrograms

Rectal Cancer


Studies of Quality (Standard 4.7)

2016 Quality Study 1: Breast Cancer Detection to Diagnosis2015 Detection to Diagnosis data reveals opportunity to improve time period from detection to diagnosis for breast cancer diagnosed at SOMC. The goal of the study was aimed to evaluate the detection to diagnosis days elapsed from initial abnormal imaging (BIRAD 4 or 5) to diagnosis of breast cancer. Review of data revealed the greatest variability in the process lies with the abnormal imaging report to the scheduled biopsy; ranging from 2 days-98 days. Controlled and uncontrolled factors influencing detection to diagnosis days were identified as:

Controlled Variables Uncontrolled Variables

Surgeon schedule Out of town surgical referral

Radiologist schedule Patient preference

Patient taking blood thinners

Twenty-five (25) patients were identified as data skewed by uncontrolled variables and therefore eliminated from further evaluation. Two (2) patients did not have a biopsy performed.

Thirty-five (35) patients were further analyzed to sub-categorize the data by the controlled variables.

Controlled Variable

Number of

Patients

Elapsed Days Comments or Trends

Surgeon schedule 29 13.5

BIRAD 4 or 5 performed on Friday did not get referred until Monday Referrals made by ordering provider created more elapsed daysUnavailability of time slots

Radiologist schedule 7 7.9

BIRAD 4 or 5 performed on Friday did not get scheduled until following weekUnavailability of time slots

13


SOMC Cancer Committee recommended measurement on FY17 BPL DB to monitor improvement along with task force creation devoted to focused breast navigation and improving performance.

2016 Quality Study 2: Social Work Distress Inventory Tool versus PROMIS Anxiety Short-Form Tool Comparison

The Social Work Distress Inventory tool (SWDI) utilized to screen patients for distress at the SOMC Cancer Center was reported by staff as having opportunities for improvement. The scale of 0-10 used to identify patients with distress concerns did not appear to correlate with the number of concerns on the problem list or the number of concerns were not the source of the distress. Furthermore, even when patients indicated a high score, no method existed to delve further into discerning the root of the distress.

The study concluded that the relationship between the departmentally developed scale and the validated tool known as PROMIS appears to be weak. These findings raised important questions related to the utility of the departmentally developed tool and pointed to data that this tool needed replacement with a validated tool. As a result, cancer committee recommended replacement of the current SWDI and replacement with a validated tool. The end result was a decision to utilize the PHQ-2 to record an initial distress score. When the initial score was positive then a more detailed PHQ-9 will be deployed.

Quality Improvements (Standard 4.8)

Two quality improvement projects were completed and reported in 2016; Genetic Counseling and Lung Cancer Detection to Diagnosis & Diagnosis to Treatment Elapsed Days.

2015 Quality Improvement Project #1: Genetic CounselingThe team set out to establish clinical guidelines for breast cancer genetic counseling referral and deploy a process across the SOMC enterprise. As a result the following actions occurred:

14


Genetic Counseling Referrals

Do (Do, Study, Act) Completed

Created formalized genetic counseling process Q3 2015

Cancer Committee approved genetic counseling policy Q4 2016

Created Genetic Counseling Referral Form Q3 2015

Created Genetic Counseling SOC Q3 2015

Provide link on SOMC Intranet for providers to access form and SOC Q4 2015

Deployed Genetic Counseling SOC Q4 2015

Added Genetic Counseling as category for discussion at Prospective Cancer Conference Q4 2015

Developed formalized genetic counseling agreement with OhioHealth Q1 2016

Cancer Committee approved process to secure funding for genetic counseling Q1 2016

Hosted joint teleconference with OhioHealth to work on small process changes and improvements Q3 2016

As a result of the above actions 69% of the patients meeting the criteria for genetic counseling received counseling in fiscal year 2016 compared to only 5% of the patients who received counseling in calendar year 2014.

2015 Quality Improvement Project #2: Lung Cancer Detection to Diagnosis & Diagnosis to Treatment Elapsed Days

The team set out to create a process to monitor and implement ways to improve detection to diagnosis and diagnosis to treatment for patients with lung cancer. As a result the following actions occurred.

15


Lung Navigation Team

Do (Do, Study, Act) Completed

Lung Navigator hired and incorporated into navigation team. Q4 2015

Created flow sheet for Lung Navigation incidental and referral process. Q4 2015

Dynalung system capabilities were explored and the system had an upgrade which provided the search options to help in identifying incidental findings.

Q2 2016

Dr. Logan educated radiologists in reading scans in L-Rad format to better track and monitor the growth of potential findings. Q1 2016

All findings on scans are communicated with lung navigation so that biopsy or specialty appointment can be scheduled quickly. Q1 2016

Pulmonology notifies lung navigator ASAP when positive biopsy is obtained so care is coordinated in a timely manner. Q1 2016

Lung cancer referrals are escalated to management when appointment is not available same week as referral. Provisions or double bookings are created to see patient quickly.

Q3 2015

Missy Hutchens developed informational packets for Lung Navigation and Physician Liaisons to take to providers in the outlying areas.

Q3 2016

The addition of the two cardio-thoracic surgeons increased the availability of appointments for diagnostic biopsies. Q2 2016

Community Health and Wellness funds are available to assist patients with transportation barriers. Q3 2016

Decision support is monitoring the final bill on patients to see if their carriers are paying for LDCT as screening services. Ongoing

Continue to discuss lung cancer cases in Tumor Board to gain multidisciplinary approach and retain services. Ongoing

Track and record the retention of lung cancers diagnosed at SOMC. Ongoing

As a result both detection to diagnosis and detection to treatment elapsed days were improved. The graph displayed below illustrates the improvement using data from calendar year 2013 and the most current data from fiscal year 2016.

Detection to Diagnosis

50

40

30

20

10

0

FY16

2013

Detection to Treatment

16


17

Vincent Scarpinato, MD, FACS, MBAGeneral Surgeon/Breast Cancer SurgeonCancer Liaison Physician Cancer Committee ChairQuality Improvement Coordinator

Thomas Summers, DO, FACOIMedical Oncology/Hematology

Ben Gill, MBAAdministration

Scott Logan, MDDiagnostic RadiologyBreast Program Leadership Chair Janan Alkilidar, MDDiagnostic Radiology

Bambi Overacre, RT(R)(MR)(CT)Medical Imaging

Donna Corcoran, RT(R)(CT)(M)Breast Imaging

Stephanie Hale, BSN, RN, CN-BNBreast Navigation

Melissa Hutchens, BS, RT (R), RDMSMedical Imaging Meghan SextonAmerican Cancer Society Rachelle Collins, RN, BSN, OCNOutpatient OncologyCommunity Outreach Coordinator Brooke CoriellOutpatient Rehabilitation Valerie DeCamp, RN, BSN, MHA, NE-BCInpatient Nursing Ann Fankell, LSW, MSW, NADIIICancer Center Social WorkPsychosocial Services Coordinator Kristi Coleman, BS, CTRCancer Registrar Linda Horner, RN, BSN, OCN, PCCNInpatient Oncology Nursing Jamie Arnett, RN, OCNClinical Research Representative

Aubrey RoyCommunity Relations

Debbie DanielsPhysician Liaison Wendi Waugh, R.T. (R)(T) CMD, CTR, BSAdministrator Cancer ServicesCancer Registry Quality Control Chair Vincent Randaisi, DO, FACPPathology Jill Preston, RN, MSNCommunity Health & Wellness Kimberlee Richendollar, RN, BSN, OCNNurse Navigation

Jennifer Woodyard, RRT, CPFTLung Navigation Chad Lore, MS, NP-CHospice and Palliative Care

Jenny Smathers, RN, BSN, CHPNPalliative Care Elie Saab, MDPulmonology Yinong Liu, MD, PhDMedical Oncology/HematologyCancer Conference Chair Elliot Navo, MD Radiation Oncology

Jessica Suber, MDPlastic Surgery

Andrea BargerPulmonology Office

Misam Zawit, MDHospitalist

Pardha Vishnumolakala, MDHospitalist

Thomas Khoury, MDGeneral Surgery

John Harcha, PA-CPhysician Assistant-Medical Oncology/Hemotology

2016 SOMC Cancer Committee Members

SOMC Cancer Center1121 Kinneys Lane | Portsmouth, OH 45662(740) 356-7490

www.somc.org/cancer/reports/

somc cancer services annual report€¦ · somc case accession summary for combined calendar years...

Documents